{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-020616","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.794778+00:00","generated_at":"2026-06-05T11:56:33.357716+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"VK2735 Phase 2 meets endpoints: up to 14.7% weight loss, 88% achieve ≥10% loss","bullets":["Primary and all secondary endpoints met; up to 14.7% mean weight loss from baseline (13.1% placebo-adjusted) after 13 weeks.","Up to 88% of VK2735-treated patients achieved ≥10% weight loss vs 4% for placebo.","No weight loss plateau observed; reductions progressive through week 13.","Well-tolerated: 92% of drug-related TEAEs mild/moderate; low discontinuation (13% vs 14% placebo).","Company plans FDA meeting to discuss next steps; oral formulation data expected this quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-020616","json":"https://secwatch.observer/filing/0000950170-24-020616.json","markdown":"https://secwatch.observer/filing/0000950170-24-020616.md","text":"https://secwatch.observer/filing/0000950170-24-020616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024020616/0000950170-24-020616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024020616/vktx-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:56:33.357716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}